219 related articles for article (PubMed ID: 10937677)
1. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction.
Lord RV; O'Grady R; Sheehan C; Field AF; Ward RL
J Gastroenterol Hepatol; 2000 Jul; 15(7):730-6. PubMed ID: 10937677
[TBL] [Abstract][Full Text] [Related]
2. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
4. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
5. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.
Chak A; Lee T; Kinnard MF; Brock W; Faulx A; Willis J; Cooper GS; Sivak MV; Goddard KA
Gut; 2002 Sep; 51(3):323-8. PubMed ID: 12171951
[TBL] [Abstract][Full Text] [Related]
6. Activation of c-K-ras mutations in human gastrointestinal tumors.
Arber N; Shapira I; Ratan J; Stern B; Hibshoosh H; Moshkowitz M; Gammon M; Fabian I; Halpern Z
Gastroenterology; 2000 Jun; 118(6):1045-50. PubMed ID: 10833479
[TBL] [Abstract][Full Text] [Related]
7. K-ras codon 12 mutations of the super-minute dysplasia in Barrett's esophagus by DNA extraction using a microdissection method.
Wada R; Yamaguchi T
Dis Esophagus; 2003; 16(3):214-7. PubMed ID: 14641312
[TBL] [Abstract][Full Text] [Related]
8. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
9. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.
Lord RV; Frommer DJ; Inder S; Tran D; Ward RL
Aust N Z J Surg; 2000 Jan; 70(1):26-33. PubMed ID: 10696939
[TBL] [Abstract][Full Text] [Related]
11. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
12. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
13. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations in malignant and premalignant Barrett's esophagus.
Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
[TBL] [Abstract][Full Text] [Related]
15. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
[TBL] [Abstract][Full Text] [Related]
16. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
17. Barrett's oesophagus--a pathologist's view.
Fléjou JF; Svrcek M
Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
19. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization.
Croft J; Parry EM; Jenkins GJ; Doak SH; Baxter JN; Griffiths AP; Brown TH; Parry JM
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1179-86. PubMed ID: 12439111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]